Evidence map›Paper›PMID 24913829›Full record

ArticleThe Prostate2014

Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription.

Lizamma Antony, Freek van der Schoor, Susan L Dalrymple, John T Isaacs

Open access · greenAbstract read
In one paragraph

Article in The Prostate, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Molecular insights for the tumor suppressor role of SPOP in prostate cancer.Biochimica et biophysica acta. Reviews on cancer · 2026
    Review
  5. Review
  6. LHX3 promotes EMT in hepatoma cell through β-catenin/TCF4 pathway.Medical oncology (Northwood, London, England) · 2024
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Lizamma AntonyChemical Therapeutics Program and Prostate Cancer Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; Department of Urology, The Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland.
Freek van der Schoor
Susan L Dalrymple
John T Isaacs
Johns Hopkins University · USSidney Kimmel Comprehensive Cancer Center · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI DENMEADE, SAMUEL R · 1992 to 2020
$43.9M
Synthesis and MAPK Kinase Inhibitiory Activities in Prostate TumorsU54CA091409 · NCI · JOHNS HOPKINS UNIVERSITY · PI BHUJWALLA, ZAVER M. · 2001 to 2010
$8.9M
Targeting of the Androgen Receptor in Prostate CancerR01DK052645 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI ISAACS, JOHN TOD · 1997 to 2005
$1.3M
NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA058236NCI NIH HHS U54 CA091409NCI NIH HHS U54CA091409NIDDK NIH HHS R01 DK052645NIDDK NIH HHS R01DK52645
6 · The paper itself

Abstract

introductionPhysiologic testosterone continuously stimulates prostate stromal cell secretion of paracrine growth factors (PGFs), which if unopposed would induce hyperplastic overgrowth of normal prostate epithelial cells (PrECs).

methodsLentiviral shRNA stable knock down of c-MYC, β-catenin, or TCF-4 completely inhibits normal (i.e., non-transformed) human PrECs growth. c-MYC enhancer driven reporter expression and growth is inhibited by two chemically distinct molecules, which prevent β-catenin signaling either by blocking TCF-4 binding (i.e., toxoflavin) or by stimulating degradation (i.e., AVX939). Recombinant DKK1 protein at a dose, which inhibits activation of canonical Wnt signaling does not inhibit PrEC growth. Nuclear β-catenin translocation and PrEC growth is prevented by both lack of PGFs or Akt inhibitor-I. Growth inhibition induced by lack of PGFs, toxoflavin, or Akt inhibitor-I is overcome by constitutive c-MYC transcription.

resultsIn the presence of continuous PGF signaling, PrEC hyperplasia is prevented by androgen binding to AR suppressing c-MYC transcription, resulting in G0 arrest/terminal differentiation independent of Rb, p21, p27, FoxP3, or down regulation of growth factors receptors and instead involves androgen-induced formation of AR/β-catenin/TCF-4 complexes, which suppress c-MYC transcription. Such suppression does not occur when AR is mutated in its zinc-finger binding domain. DISCUSSION: Proliferation of non-transformed human PrECs is dependent upon c-MYC transcription via formation/binding of β-catenin/TCF-4 complexes at both 5' and 3' c-MYC enhancers stimulated by Wnt-independent, PGF induced Akt signaling. In the presence of continuous PGF signaling, PrEC hyperplasia is prevented by androgen-induced formation of AR/β-catenin/TCF-4 complexes, which retains binding to 3' c-MYC enhancer, but now suppresses c-MYC transcription.

Indexed as

Cell ProliferationBasic Helix-Loop-Helix Leucine Zipper Transcription Factorsbeta CateninCells, CulturedEpithelial CellsForkhead Transcription FactorsHumansIntercellular Signaling Peptides and ProteinsMaleProstateProstatic HyperplasiaProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mycReceptors, AndrogenRNA, Small InterferingSignal TransductionBasic Helix-Loop-Helix Leucine Zipper Transcription Factorsbeta CateninDKK1 protein, humanForkhead Transcription FactorsFOXP3 protein, humanIntercellular Signaling Peptides and ProteinsMYC protein, humanProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mycReceptors, AndrogenRNA, Small InterferingTCF4 protein, humanTranscription Factor 4Transcription Factorsandrogen receptorc-MYC, β-cateninhuman prostate epithelial cellsTCF-4

Identifiers

PMID24913829
PMCPMC4856018
OpenAlexW1526435092

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.